Use: The anti-PM/Scl-100 antibody is associated with younger age, calcinosis and has lower rates of gastrointestinal symptoms, ILD and pulmonary hypertension. There is also evidence of a possibly better survival compared to the presence of either anti-PM/Scl-75 or anti-Scl-70 antibodies.

Limitations: This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

Methodology: Enzyme-linked immunosorbent assay (ELISA)